Keyphrases
Disease-modifying Antirheumatic Drugs (DMARDs)
50%
Disease-modifying Therapy
50%
FDG PET-CT
100%
Hydroxychloroquine
50%
Joint Counts
50%
Joint Evaluation
50%
Lack of Response
50%
Methotrexate
100%
Methotrexate Chemotherapy
50%
Multiple Sites
50%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Rheumatologists
50%
Sulfasalazine
50%
Treatment Assignment
100%
Treatment Regimen
50%
Trial Design
50%
Triple Therapy
50%
Tumour Necrosis Factor Inhibitor (TNFi)
50%
Unblinding
50%
Vascular Inflammation
50%
Medicine and Dentistry
Arm
33%
Disease-Modifying Antirheumatic Drug
33%
Diseases
33%
Hydroxychloroquine
33%
Methotrexate
100%
Monotherapy
33%
Positron Emission Tomography-Computed Tomography
100%
Randomized Controlled Trial
66%
Salazosulfapyridine
33%
TNF Inhibitor
33%
Vasculitis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
33%
Hydroxychloroquine
33%
Methotrexate
100%
Monotherapy
33%
Polyethylene Terephthalate
100%
Randomized Controlled Trial
66%
Sulfasalazine
33%
Tumor Necrosis Factor Inhibitor
33%
Vasculitis
33%